8-K: Liquidia Reports Strong 2025 YUTREPIA Sales, Profitability

Liquidia Corporation announced robust full-year 2025 financial results, driven by strong YUTREPIA sales and achieving its second consecutive quarter of profitability.

Summary

• Full year 2025 YUTREPIA net product sales reached $148.3 million, with $90.1 million generated in the fourth quarter.
• More than 3,600 unique prescriptions for YUTREPIA have been received and over 2,900 patients treated since its launch in June 2025.
• The company ended 2025 with $190.7 million in cash and cash equivalents, marking an increase of $33 million from the third quarter.
• Liquidia recorded its second consecutive quarter of profitability, with a net income of $14.6 million and positive non-GAAP adjusted EBITDA of $27.3 million in the fourth quarter of 2025.
• Net loss for the full year 2025 was $68.9 million, or $0.80 per basic and diluted share, a significant improvement from a net loss of $128.3 million, or $1.63 per share, for the full year 2024.
• Research and development expenses decreased by $8.5 million (18%) to $39.3 million in 2025, primarily due to a shift towards commercialization activities and reduced YUTREPIA R&D expenses, offset by increased L606 clinical expenses.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong commercial execution for YUTREPIA, rapid market adoption, and a significant shift to profitability, indicating robust operational performance and future growth potential despite ongoing litigation.

Positives

• YUTREPIA net product sales reached $148.3 million for the full year 2025, with $90.1 million in the fourth quarter, demonstrating strong market adoption post-launch.
• Over 3,600 unique prescriptions received and more than 2,900 patients treated with YUTREPIA since its June 2025 launch, indicating rapid patient uptake.
• Prescription-to-start conversion for YUTREPIA remained strong at or above the 85% level reported in the third quarter of 2025.
• The total number of YUTREPIA prescribers increased to approximately 860, with over half prescribing to at least 2 patients and 25% referring 5 or more.
• Ended 2025 with a robust cash and cash equivalents balance of $190.7 million, an increase of $33 million from the third quarter.
• Achieved second consecutive quarter of profitability, reporting net income of $14.6 million and positive non-GAAP adjusted EBITDA of $27.3 million in Q4 2025.
• Net loss for the full year 2025 significantly improved to $68.9 million, compared to $128.3 million in 2024, reflecting enhanced financial performance.

Negatives

• Service revenue, net, decreased by $4.0 million to $10.0 million for the year ended December 31, 2025, compared to $14.0 million in 2024, primarily due to lower sales volumes of Treprostinil Injection.
• Selling, general and administrative expenses increased significantly by $75.6 million (93%) to $157.2 million for the year ended December 31, 2025, driven by commercialization efforts, higher headcount, and increased legal fees.
• Total other expenses, net, increased by $10.5 million to $17.5 million for the year ended December 31, 2025, primarily attributable to higher borrowings under the revenue interest financing agreement.

Risks

• The ability to maintain YUTREPIA's approval and continue its commercialization is subject to ongoing litigation with United Therapeutics, which is seeking injunctive relief that could block sales for PAH and/or PH-ILD.
• Future results of operations and financial position, strategic and financial initiatives, business strategy, and objectives are subject to significant risks and uncertainties.
• Clinical trials, clinical studies, regulatory applications, patent litigation outcomes, and the issuance of patents involve significant risks and uncertainties.
• Estimates regarding future expenses, capital requirements, needs for additional financing, and potential revenue and profitability of YUTREPIA involve significant risks and uncertainties.
• Operating in a very competitive and rapidly changing environment with inherent industry risks, including the emergence of new risks.

Future Outlook

Liquidia plans to deepen prescriber adoption for YUTREPIA, grow its sales force, expand YUTREPIA's clinical evidence through multiple new studies, and advance L606 into pivotal trials, all of which will be funded from operations. The company believes YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.

Management Comments

• "As we close 2025, we are encouraged by how quickly YUTREPIA has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories." Dr. Roger Jeffs, CEO.
• "Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies." Dr. Roger Jeffs, CEO.
• "Having increased profitability in our second full quarter after launch, we will build on this foundation in 2026 from a position of financial strength." Dr. Roger Jeffs, CEO.
• "We plan to deepen prescriber adoption, grow our sales force, expand YUTREPIA’s clinical evidence through multiple new studies, and advance L606 into pivotal trials, all of which will be funded from operations." Dr. Roger Jeffs, CEO.
• "We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases." Dr. Roger Jeffs, CEO.

Industry Context

StockSavvy.ai notes that YUTREPIA's rapid adoption and strong initial sales position it as a significant entrant in the pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) markets, which are characterized by high unmet medical needs and a focus on improving patient quality of life and exercise ability. The company's focus on expanding clinical evidence and advancing L606 suggests a strategy to solidify its market position and address broader cardiopulmonary diseases, potentially challenging existing therapies like United Therapeutics' Remodulin.

Comparison to Industry Standards

• YUTREPIA's launch performance is noted as "among one of the top specialty drug launches over the past five years across all therapeutic categories," indicating superior initial market penetration compared to many new drug introductions.
• Liquidia's Treprostinil Injection, a generic version, directly competes with branded drugs like United Therapeutics' Remodulin, offering a lower price point while maintaining similar service and support, which is a competitive advantage in the generic market.

Legal Proceedings

• Ongoing litigation with United Therapeutics in the U.S. District Court for the District of Delaware and U.S. District Court for the Middle District of North Carolina related to YUTREPIA.
• United Therapeutics is seeking injunctive relief that could block Liquidia's ability to continue selling YUTREPIA for PAH and/or PH-ILD.

Stakeholder Impact

• Shareholders: Positive impact due to strong YUTREPIA sales, profitability, and improved financial position, potentially leading to increased shareholder value. However, ongoing litigation poses a significant risk to future revenue streams.
• Patients: Improved access to YUTREPIA for PAH and PH-ILD, offering a new, convenient treatment option designed to improve exercise ability and quality of life.
• Prescribers: Growing confidence and adoption of YUTREPIA among approximately 860 prescribers, with increasing depth in treatment centers, indicating positive clinical experience and integration into practice.
• Employees: Potential for sales force expansion and continued investment in R&D programs like L606 suggests job stability and growth opportunities within the company.
• Creditors: Improved financial health, including profitability and a strong cash position, may enhance the company's creditworthiness and ability to manage existing debt obligations.

Next Steps

• Deepen prescriber adoption for YUTREPIA.
• Grow the sales force.
• Expand YUTREPIA's clinical evidence through multiple new studies.
• Advance L606 into pivotal trials.
• Host a webcast on March 5, 2026, to discuss financial results and provide a corporate update.

Key Dates

Recommendation

The strong commercial launch of YUTREPIA, achieving $148.3 million in sales in its first partial year and driving the company to profitability in Q4 2025, demonstrates exceptional market penetration and product acceptance. The significant improvement in net loss year-over-year and a healthy cash position provide a strong financial foundation for future growth initiatives, including expanding the sales force and advancing L606. While ongoing litigation with United Therapeutics presents a material risk, the current operational momentum and market success of YUTREPIA suggest substantial upside potential, making it a compelling "strong buy" for investors willing to monitor the legal developments.

Keywords

Liquidia Corporation, LQDA, YUTREPIA, treprostinil, PAH, PH-ILD, pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, biopharmaceutical, financial results, Q4 2025, full year 2025, drug launch, L606, PRINT technology, SEC filing, 8-K